EVE Health Group (ASX: EVE) has received its first commercial purchase order for Dyspro, a proprietary gummy-format pharmaceutical product designed to help women experiencing dysmenorrhoea (painful menstruation) and related health concerns. EVE Health Group is focused on developing, manufacturing, and marketing natural health products and prescription medicines. Dyspro is a pharmaceutical-grade formulation containing a validated blend of cannabinoid-derived active ingredients and marks EVE’s initial internally-developed product to advance from formulation to large-scale manufacturing.
The order follows EVE’s recent acquisition of Nextract, expanding its footprint into prescription pharmaceutical products. According to EVE executive director and chief scientific officer Dr Stuart Gunzburg, the commercial order signifies a crucial milestone, demonstrating the company’s ‘readiness to deliver’ on its growth strategy. He added that this order represents the translation of their internal formulation efforts into a tangible product aimed at supporting women’s health through regulated prescription channels.
EVE Health plans to supply the Dyspro order from its GMP-certified Australian manufacturing facility and anticipates distribution to commence within five weeks. The company is currently evaluating national distribution options, seeking pharmaceutical logistics partners capable of ensuring timely access, adherence to regulatory requirements, and scalable infrastructure to accommodate anticipated demand. Dyspro is already accessible to authorised prescribers in Australia, with no additional regulatory hurdles preventing commercial supply.
Dysmenorrhoea is a prevalent condition affecting many Australian women of reproductive age, often significantly impacting daily activities and leading to lost productivity. The global market for dysmenorrhoea treatments reached US$10.9 billion in 2024 across major pharmaceutical markets and is projected to double in value by 2035. The Australian endometriosis treatment market, frequently linked to dysmenorrhoea, is forecast to reach US$76.4 million by 2030.
